According to the National Health and Medical Research Council – NHMRC clinical trials across Australia are in the following categories:
– treatment trials to test new treatments, new medicines or combinations of medicines; or other new therapies such as surgery, the use of new medical devices or new approaches to surgery
– diagnostic or screening trials to evaluate tests or procedures to diagnose and detect diseases or conditions
– prevention trials to test new ways to prevent disease including medicines, vaccines, vitamins, or changes to diet, lifestyle or behaviour
Clinical trials in Australia need to be efficiently administrated and resourced with qualified healthcare professionals as well as suitable patients.
Shanny Dyer, CEO ARCS Australia talks about a recent summit where the CRO (Contract Research Organization) community was asked on the current state of clinical trials in Australia. Commentary from:
– Tanya Symons, Director at T Symons Associates
– Daniela Caiazza, Director Clinical Operations ANZ, Novotech CRO
– Adam Stoneley, Research Operations Manager, Icon Cancer Centre
– Gabrielle McKee, Chief Operating Officer, CNS Clinical Network
– Joe Taouk, Senior Director Research and Development, IQVIA
#AustralianHealthJournal #ClinicalTrials
-
HEALTH CARE BRIEF: Venous thromboembolism (VTE)
Venous thromboembolism (VTE) – Incidence rates, symptoms, risks, research & innovation
-
ARCS Australia
ARCS Australia Ltd is a national, membership-based organisation focused on the development and growth of the healthcare sector. ARCS provides education, career pathways, professional development and advocacy to the healthcare sector.
Our membership is made up of individuals working in regulatory affairs, clinical research, health economics, medical information and other disciplines who work in the development and quality use of therapeutic goods. ARCS members are based in industry, academia, medical research institutes, government, hospitals and patient groups.
Through its members ARCS has a broad and effective reach throughout the healthcare sector, and provides a neutral forum to develop, agree and implement aligned policies and initiatives.ARCS and its members are dedicated to improving the quality of life of healthcare consumers.
MEDIA PARTNER SINCE 2018
-
-
ICTD: Why negative results in clinical trials matter
To mark International Clinical Trials Day 2026, Australian Health Journal commences a 4 part special series leaving up to 20th May. Through conversations with leading researchers, clinicians and trial organisations, the series highlights achievements in the year that was for clinical trials.
Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.
